Adenosine for the Management of Neonatal and Pediatric Supraventricular Tachycardia

Contributing Editor: Marcia L. Buck, Pharm.D.; Editorial Board: Kristi N. Hofer, Pharm.D.; Michelle W. McCarthy, Pharm.D.


Pediatr Pharm. 2008;14(8) 

In This Article


Supraventricular tachycardia (SVT) is the most common symptomatic arrhythmia of childhood, occurring in 1 in 250 to 1,000 children.[1,2] In October 1989, adenosine was approved by the Food and Drug Administration (FDA) for the conversion of paroxysmal supraventricular tachycardia (SVT) to sinus rhythm.[3,4] Even before approval by the FDA, adenosine was studied in the management of infants and children with SVT.[5,6] Some of the initial studies were conducted at the University of Virginia by John DiMarco and colleagues, who were also involved in its development.[6] Twenty years of accumulated experience have substantiated the efficacy of adenosine and revealed a relatively low incidence of serious adverse effects in patients who undergo treatment. This issue of Pediatric Pharmacotherapy will provide an overview of adenosine and provide recommendations for its use in infants and children with SVT.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: